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Case presentation
Patient 1. An 18-year-old woman with cystic fibrosis was admitted to
the hospital for evaluation of shortness of breath and a productive
cough of one week duration. She had required hospitalization for
pneumonia at ages 12 and 16 and again 6 months prior to the present
admission. Fat malabsorption (30—50 g/day) and an elevated sweat
chloride concentration had been documented. Medications at the time
of admission included trimethoprim-sulfamethoxazole, one tablet twice
daily; theophylline; and a pancreatic enzyme preparation.
Weight was 37 kg; temperature, 37°C; respiratory rate, 20/mm; blood
pressure, 104/76 mm Hg supine and 102/64 mm Hg upright. Pertinent
physical findings included: clubbing of finger nails; diffuse coarse rales,
rhonchi, and wheezes throughout the chest; and moist mucous mem-
branes. There was no cyanosis or edema and skin turgor was normal.
Laboratory data revealed: hemoglobin, 12,5 g/dl; white blood cell
count, l5,000/mm (80% neutrophils, 4% bands, 13% lymphocytes);
normal prothrombin time and Pri'; albumin, 2.7 g/dl; BUN and
creatinine, 6 and 0.5 mg/dl, respectively; and glucose, 96 mgldl. Serum
electrolytes were: sodium, 136; potassium, 3.5; chloride, 96; and total
CO2. 28 mEq/liter. Arterial blood gas measurements, obtained while the
patient was breathing 4 liters of oxygen by nasal prongs, revealed a P02
of 67 mm Hg, a PCO2 of 40 mm Hg, and a pH of 7.50. Chest x-ray
disclosed bibasilar and right middle lobe infiltrates. Sputum culture
grew large numbers of Staphylococcus aureus and pseudomonas spe-
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cies. The patient was treated with gentamicin, carbenicillin, and intra-
venous hypotonic fluids. Postural drainage also was employed. Two
days later the serum sodium was 129; potassium, 3.5; chloride, 93; and
total C02, 27 mEq/liter. Random urinary sodium was 74 mEq/liter and
urine osmolality was 500 mOsm/kg H20. The patient was enrolled in a
research protocol for elucidating the pathophysiology of hyponatremia.
The following hormone measurements were obtained while she was
supine: norepinephrine, 469 pg/mI; epinephrine, 190 pg/mI; plasma
renin activity, 2.1 ng/ml/hr; plasma aldosterone, 4.3 ng/dl; and plasma
arginine vasopressin, 2.1 pg/mI. Two liters of normal saline were
administered, but neither body weight nor serum sodium concentration
changed. The patient's course was complicated by a pneumothorax that
required chest tube drainage. She was discharged 25 days after admis-
sion. At that time the serum sodium was 135; potassium, 3.9; chloride,
96; and total CO2. 31 mEq/liter.
Patient 2. A 54-year-old woman was admitted to the hospital for
elective repair of a Nisson fundal plication that had been performed
because of severe reflux esophagitis. Physical examination was unre-
markable. Preoperative laboratory data revealed: a normal complete
blood count; serum creatinine, 1.1 mg/dl; and glucose, 88 mg/dl. Serum
electrolytes were: sodium, 141; potassium, 4.1; chloride, 100; and total
C02, 25 mEq/liter. The operative procedure was uncomplicated. On the
first postoperative day, serum electrolytes were: sodium, 129; potassi-
um, 3.5; chloride, 94; and total CO2. 24 mEq/liter. Serum creatinine was
0.8 mg/dl; glucose, 108 mg/dl; random urinary sodium, 58 mEq/liter;
and urine osmolality 450 mOsmlkg H20. The patient was asymptomat-
ic. She had received 9000 ml of hypotonic fluid (0.45% and 0.2% saline)
and had a urinary output of approximately 4 liters. Plasma arginine
vasopressin was 1.8 pg/mI. Hypotonic fluid administration was discon-
tinued and the patient's serum sodium concentration rose to 140 mEq/
liter over the next 3 days.
Discussion
DR. ROBERT J. ANDERSON (Head of Medical Service, Veter-
ans Administration Hospital, and Professor of Medicine, Uni-
versity of Colorado Health Sciences Center, Denver, Colora-
do): Hyponatremia is a common occurrence in hospitalized
patients. In 1968, Owen and Campbell published frequency
distribution curves that showed mean plasma sodium and
chloride concentrations 5 to 6 mEq/liter lower in hospitalized
patients than in healthy outpatient control subjects [1] (Fig. 1).
Mean plasma potassium and bicarbonate concentrations were
comparable in the two groups. In a recent prospective study,
we found daily incidence and prevalence rates of hyponatremia
(serum sodium, <130 mEq/liter) of approximately 1% and 2.5%
respectively, in hospitalized patients on general, medical-surgi-
cal wards [2]. Hyponatremia not only is a frequent occurrence,
it also is associated with substantial morbidity and mortality [3—
6]. Because I believe that an understanding of the pathophysiol-
ogy of hospital-associated hyponatremia can lead to its preven-
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tion, I wish to emphasize in this discussion the mechanisms that
lead to this common electrolyte disturbance. I also plan to
discuss the clinical settings in which hospital-associated hypo-
natremia occurs and the management and outcome of patients
who develop it.
Pathophysiologic considerations
All cells actively extrude sodium ions from their interior, and
their low permeability to sodium limits its passive re-entry.
Thus sodium and its accompanying anions are the major
extracellular solutes, with glucose, urea, and other ions contrib-
uting to a lesser degree. As a corollary, sodium and its
accompanying anions are the main determinant of plasma
osmolality. Because virtually all body water is in osmotic
equilibrium, an acute lowering of the plasma sodium concentra-
tion due to relative water excess leads to an osmotic gradient
and to a movement of water from the extracellular to intracellu-
lar compartments [6]. The resultant cerebral edema coupled
with the brain's rigid encasement can lead to significant neuro-
logic symptoms and morbidity [3—6].
Many years ago Edelman and associates found that the serum
sodium concentration depended on the following relationship
[7]:
Total body sodium + total body potassiumSerum sodium = Total body water
Thus, as every medical student recognizes, the plasma concen-
tration of sodium reflects the prevailing relationship between
solute and water balance and not the absolute amount of either
solute or water present in the body. The absolute amounts of
sodium and water do determine the extracellular fluid volume.
In my experience, a reduction in plasma sodium concentration
in hospitalized patients is most often due to an increase in total
body water. Such an increase implies continued water intake in
the presence of a decreased capacity for water elimination.
Appropriate elimination of ingested water is, of course, the
consequence of the kidney's normal response to suppressed
arginine vasopressin (AVP). Ingestion of a water load directly
reduces plasma osmolality; hypoosmolality in turn suppresses
hypothalamic synthesis and posterior pituitary release of AVP
[8]. Arginine vasopressin normally increases the permeability of
the apical surface of renal collecting tubular epithelial cells to
water. In the presence of a hypertonic interstitial environment
surrounding the collecting duct, the increase in water perme-
ability induced by AVP results in renal water retention. Sup-
pression of AVP by hypoosmolality allows excretion of the
water load. However, a large body of experimental evidence
has shown conclusively that continued secretion of vasopressin
can occur despite hypoosmolality, thus establishing the exis-
tence of so-called nonosmotic stimuli for vasopressin secretion
[8]. Examples of clinical conditions associated with such stimuli
include cardiovascular instability, edematous and volume-
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depleted states, glucocorticoid deficiency, hypothyroidism, de-
rangements of arterial blood gases, the postoperative state, and
certain malignancies [2, 5, 9—15].
We recently studied the circulating levels of several hor-
mones in 72 patients with hospital-associated hyponatremia; we
were especially interested in the possible pathogenetic role of
AVP in this disorder [2]. We detected AVP in the plasma of 71
of 72 hyponatremic patients. The majority of patients with
hospital-associated hyponatremia were receiving hypotonic flu-
id intravenously [2]. The combination of high plasma AVP and
hypotonic fluid administration leads to water retention and to
hyponatremia.
In an effort to determine the cause of the nonosmotic
secretion of AVP in these patients, we measured plasma
concentrations of renin activity, norepinephrine, and aldoster-
one. In patients with edema or hypovolemia, measurements of
mean arterial blood pressure (low), pulse rate (high), and of
plasma norepinephrine, aldosterone, and renin activity (all of
which are increased) suggest baroreceptor-mediated, nonos-
motic release of AVP [2]. However, many of the patients we
studied and the patients under discussion today had no evi-
dence of volume depletion or cardiovascular instability and
normal plasma concentrations of renin activity and aldosterone.
Thus, the cause of the nonosmotic release of AVP in these
patients remains unknown.
For a water load to be excreted normally, other aspects of
renal function in addition to ADH-responsiveness must be
operating properly. For example, normal rates of glomerular
filtration and proximal tubular reabsorption are necessary to
deliver a sufficient quantity of tubular fluid to the distal neph-
ron. Thus, as is well known, excessive water intake in the
presence of renal failure leads to water retention, positive water
balance, and hyponatremia. It is possible that increased proxi-
mal reabsorption accounts for some of the impairment of renal
diluting capacity in certain edematous patients [8].
In summary, hospital-associated hyponatremia is often due to
an increase in body water relative to the major extracellular
fluid body solute, sodium. Thus hyponatremia can occur in the
presence of either normal, decreased, or increased total body
serum. This increase in body water is often encountered in
clinically normovolemic patients and is caused by the intrave-
nous administration of hypotonic fluid to patients unable to
excrete water normally because of a nonosmotic stimulus to
AVP secretion.
Clinical approach
A comparison of some of the findings from two surveys of
hospital-associated hyponatremia is presented in Table 1. Hy-
ponatremia, as it is currently encountered, is often a hospital-
acquired disorder occurring in elderly patients with severe
underlying disease [2, 151. Table 2 details the clinical setting in
which hyponatremia occurred in 194 patients we studied pro-
spectively. In 30% of the patients, hyponatremia could be
attributed either to hyperglycemia, to severe renal failure (and
free water administration), or to laboratory error. Thus, these
three possibilities should be considered early in the diagnostic
evaluation of the hyponatremic patient.
The remaining 70% of hyponatremic patients included in
Table 2 were classified according to clinical assessment of
extracellular fluid volume, as is common in clinical practice
Table 1. Hyponatremia in hospitalized patients
Baran et al
[2]a
Anderson et al
[15]a
(n = 78) (n = 194)
Definition (mEqiliter)
Percentage of males
Mean age (years)
Mortality (%)
Hospital acquired (%)
<128
49
65
27
67
<130
50
58
11
67
Numbers in brackets refer to reference.
Table 2. Clinical setting of hyponatremia among inpatients at the
University of Colorado Hospital
Setting Percentage
Normovolemia 34
Hypovolemia 19
Edema 17
Hyperglycemia 16
Renal failure 9
Laboratory errorb 5
Data are from Ref. 2.
b All patients had confirmatory studies.
[16—191. Hyponatremia occurring in patients with an edematous
disorder (28 with cardiac failure, 6 with liver disease, and 4 with
hypoalbuminemia without liver disease) was seen in 19.4%.
Hypovolemic disorders (9 patients with gastrointestinal losses,
8 with diuretic use, 7 with combined gastrointestinal losses and
diuretic use, 4 in the postoperative state, and 5 with miscella-
neous conditions) accounted for 16.8% of hyponatremia. The
clinical setting of the 34% of hyponatremic patients who were
normovolemic included the immediate postoperative period (0
to 72 hours) (20 patients), active intracranial disease (11 pa-
tients), disseminated cancer (11 patients), administration of
pharmacologic agents known to impair renal water excretion (6
patients), massive (>12 liters) fluid resuscitation therapy for
extensive burns (3 patients), pneumonia (3 patients), more than
one of the above conditions (8 patients), and miscellaneous
conditions (4 patients). The 66 normovolemic patients (mean
urinary sodium concentration, 71 + 3.8 mEq/liter) comprised
the largest single group. By conventional criteria [2 1—23] most
of these normovolemic patients would be diagnosed as having
the syndrome of inappropriate secretion of antidiuretic hormone
(SIADH). Within barely 25 years of first being described, this
syndrome has become the most commonly recognized cause of
hyponatremia among hospitalized patients [21]. Dr. Martinez-
Maldonado presented an excellent discussion of SIADH in anoth-
er Nephrology Forum [23]. Today I would like to focus on
hyponatremia in patients with pulmonary disorders and in those in
the postoperative state, because these two circumstances are
encountered so frequently in hospitalized patients and because the
hyponatremia is usually normovolemic.
The first patient presented today appears to have SIADH
associated with intrathoracic disease that had resulted from
complications of cystic fibrosis. A number of pulmonary pro-
cesses have been reported to cause SIADH (Table 3). The
underlying mechanisms whereby intrathoracic disease process-
es lead to nonosmotic release of AVP are not clearly under-
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Table 3. Pulmonary disorders associated with hyponatremiaa
Acute respiratory failure
Severe chronic obstructive pulmonary disease
Acute bronchial asthma
Prolonged mechanical ventilation
Intrathoracic infectious processes
intrathoracic neoplasms
a Data are from Ref. 12.
Table 4. Mechanisms underlying nonosmotic secretion of AVP in
pulmonary disordersa
Hypoxemia and hypercapnic acidosis
Hemodynamic abnormalities
Unregulated synthesis and release of AVP by the tumor
Pharmacologic agents
Stress
a Data are from Ref. 12.
stood. Possible mechanisms are listed in Table 4. Experimental
and clinical studies indicate that hypoxemia as well as hyper-
capnia can cause release of AVP [11—14, 24, 25]. For example,
in the conscious dog, both hypoxemia and hypercapnic acidosis
increase plasma AVP without producing an increase in plasma
osmolality. Combined hypoxemia and hypercapnic acidosis
markedly increase plasma AVP (Fig. 2). In the clinical setting,
abrupt decreases in P02 and increases in PCO2 also are often
associated with AVP release [11]. We have found marked
increases in plasma AVP in hypoxemic and hypercapnic pa-
tients with acute respiratory failure (Fig. 3). These elevated
AVP levels slowly returned towards normal with improvement
in hypoxemia and hypercapnia.
It is also likely that hemodynamic abnormalities contribute to
release of AVP in some patients with pulmonary diseases. For
example, hypoxemia and hypercapnic acidosis lower peripheral
vascular resistance [13, 14]. Concomitant cardiac failure fre-
quently is present in patients with severe lung disease and can,
by hemodynamic mechanisms, lead to AVP release [9].
Mechanical ventilation is one clinical setting in which hemo-
dynamic alterations appear to play a key role in nonosmotic
release of AVP. Retrospective clinical observations by Sladen
et al in 1968 first suggested that mechanical ventilation can
result in renal water retention [26]. In these studies, 19 of 100
patients requiring prolonged mechanical ventilation developed
water retention. None of the patients had clinical evidence of
cardiac failure, but 11 of 19 had evidence of pulmonary edema
on chest x-ray. A significant increase in body weight (2.6 kg)
due to positive water balance (3.8 liters) and a decrease in
hematocrit and plasma sodium concentration (-5.8 mEq/liter)
were noted. With water restriction and diuretic therapy, body
weight and plasma sodium concentration returned to baseline
levels and pulmonary edema resolved.
Recent studies in anesthetized dogs have uncovered mecha-
nisms that may explain the stimulation of AVP induced by
positive end-expiratory pressure (PEEP) ventilation [27]. In
these studies both 10 and 15 cm H20 PEEP increased plasma
AVP and decreased mean arterial pressure and cardiac output.
The ability of PEEP to increase AVP was partially attenuated
by three maneuvers: plasma volume expansion (which damp-
ened the hemodynamic effects of PEEP), cervical baroreceptor
denervation, and normalization of the associated increase in
intracranial pressure [27]. The combination of baroreceptor
denervation and control of intracranial pressure nearly abol-
ished the PEEP-induced increase in AVP. These observations
suggest that the central hemodynamic effects plus the associat-
ed increase in intracranial pressure are major factors underlying
AVP release during PEEP ventilation.
Although an association of intrathoracic infections and neo-
plastic processes with hyponatremia has been known for sever-
I
Control Hypoxemia Hypercapnia Hypoxemia
+
Hypercapnia
Fig. 2. Effect of hypoxemia and hypercapnia on plasma arginine
vasopressin (AVP) in conscious dogs. Adapted from Ref. 13.
al years, the mechanism(s) responsible for this form of hypona-
tremia are not clearly established [28, 29], Amatruda and
coworkers suggested in 1963 that ectopic AVP production
might account for SIADH associated with lung neoplasms [30].
These authors were able to find AVP-like bioactivity in tumor
extracts. Substantial data suggest that bronchogenic carcino-
mas, particularly of the "oat cell" type, are capable of unregu-
lated synthesis and release of AVP. These observations in-
clude: failure of centrally acting inhibitors of ADH release (for
example, alcohol, hydantoin) to ameliorate the syndrome; the
presence of ADH-like activity by bioassay and radioim-
munoassay in tumor extracts and plasma; the incorporation of
radioactive phenylalanine by tumor slices in vitro into the same
chromatographic peak with AVP; electron microscopic evi-
dence of secretory granules in tumor specimens from patients
with the syndrome; identification of neurophysins (carrier pro-
teins of AVP) in tumor specimens; and resolution of the
syndrome after surgical removal of the tumor [12, 30—32].
Whereas bronchogenic carcinomas clearly can synthesize
AVP, the mechanism of AVP secretion associated with intra-
thoracic infectious processes is less apparent. The association
between tuberculosis and hyponatremia has been known for
years [28, 29, 33, 34]. Several investigators have demonstrated
intact adrenal and renal function as well as the absence of
volume depletion in hyponatremic patients with tuberculosis
[29, 33]. Shalhoub and Antoniou suggested that unregulated
neurohypophyseal release of ADH might account for the hy-
ponatremia in patients with tuberculosis [331. Water-loading
tests performed on 6 patients with hyponatremia and tuberculo-
sis demonstrated decreased renal water excretion in 5. This
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Fig. 3. Effect of acute respiratory failure on plasma arginine vasopres-
sin (AVP) in patients with acute respiratory failure (hatched bars) and
patients admitted with chest pain (open bars).
abnormal response was abrogated or improved in all after
ethanol administration [33]. Vorherr et a! demonstrated antidi-
uretic activity in involved lung tissue and in urine in a patient
with far-advanced tuberculosis [34]. By bioassay, antidiuretic
activity was highest in the active inflammatory zone, lower in
the central caseous zone, and absent in uninvolved tissue [341.
Neither a suspension of Mycobacterium tuberculosis nor cul-
ture media containing its metabolites demonstrated any antidi-
uretic bioactivity. These investigators postulated that pulmo-
nary tuberculous lesions may synthesize and liberate ADH in a
fashion similar to that occurring in bronchogenic carcinoma,
although passive adsorption of AVP was not ruled out. No
further examination of this hypothesis has been published.
As in the patient under discussion, SIADH also has been
documented in a variety of nontuberculous pulmonary infec-
tions. Thus, cavitary aspergillosis, acute bacterial and viral
(adenovirus 7 and 12) pneumonias, and chronic infectious
pneumonitis all have been associated with SIADH [35]. The
precise mechanism of AVP secretion in nontuberculous pulmo-
nary infections remains to be clarified. In summary, factors that
might have contributed to stimulation of AVP in the first patient
discussed include hypoxemia, pulmonary infection, hemody-
namic abnormalities, and possibly pharmacologic agents and
stress.
The second patient developed hyponatremia in the immediate
postoperative state. A recent prospective study demonstrated
that 25% of hospital-acquired hyponatremia occurred during the
postoperative period [2, 15]. A minimal estimate of the frequen-
cy of postoperative hyponatremia was 4.4% of 1088 consecutive
operative procedures [15]. Other reports suggest an even higher
frequency (Table 5) [36—50].
What is the pathogenesis of postoperative hyponatremia?
The postoperative state long has been known to be character-
ized by avid renal sodium and water retention [40, 41, 44—46].
Release of AVP from the posterior pituitary appears to be partly
responsible for the renal water retention. Bioassay and radioim-
munoassay results demonstrate high plasma AVP concentra-
tions following anesthesia and surgery [15, 44—53]. Although the
Table 5. Frequency of postoperative hyponatremiaa
Procedure Percentage
Cardiovascular 20—30
Gastrointestinal 20—60
Spinal fusion 20
T-tube drainage 22
Mitral valve surgery 30
General surgery/trauma 40
Subtotal gastrectomy 67
a Data are from Refs. 15, 36—53.
increase in plasma AVP usually subsides about 72 hours after
operation [8], it can persist for up to 5 days [50]. The precise
mechanism whereby the operative state leads to secretion of
AVP has not been ascertained.
In the presence of circulating AVP, administration of hypo-
tonic fluid and rarely isotonic fluid (if urinary osmolality is very
high) results in renal water retention and hyponatremia [54].
Indeed, 94% of postoperative hyponatremic patients in a recent
study were receiving hypotonic fluids at the time hyponatremia
developed [15]; this observation has been confirmed by others
[36, 39, 40, 48, 53, 55]. In two previous studies in which the
daily postoperative requirement for electrolyte was given in
either an isotonic or hypotonic solution, hyponatremia occurred
only in patients receiving hypotonic fluids [36, 52].
What are the consequences of postoperative hyponatremia?
None of the postoperative patients with mild hyponatremia
(serum sodium, 128 mEq/liter) in a recent prospective study
developed clinically obvious neurologic deterioration concomi-
tant with the onset of hyponatremia [15]. Another report
demonstrated the occasional development of severe neurologic
dysfunction and death in some patients with severe postopera-
tive hyponatremia, however (serum sodium <110 mEqlliter)
[5]. Finally, in edematous postoperative patients, the observed
water retention was associated with increasing pulmonary
capillary wedge pressure and radiographic evidence of pulmo-
nary vascular congestion [15].
Outcome determinants in patients with hyponatremia
I would now like to discuss the association between hypona-
tremia and poor clinical outcomes. Hyponatremia did not
appear to be associated with a poor outcome in either of the
patients discussed today. Figure 4 demonstrates, however, that
hyponatremia is a marker for poor outcome in several disease
states [56—59]. Substantial evidence suggests that mild hypona-
tremia, as in the 2 patients discussed, usually is asymptomatic
and is associated with little increase in morbidity or mortality
[2, 16]. In fact, more severe hyponatremia probably is associat-
ed with a high mortality rate merely because it is an accompani-
ment of severe underlying disease. Many patients with hypona-
tremia are extremely sick with advanced heart, liver, or lung
disease or with cancer [2, 3, 16]. Flear and Hilton have
demonstrated that the likelihood of developing hyponatremia
after myocardial infarction is a direct function of the extent and
complications of the infarction [56]. Hyponatremia is rare with
mild heart failure but more common with increasingly severe
cardiac dysfunction. In other clinical settings, such as tubercu-
losis and childhood diarrhea in the third world, hyponatremia is
more likely to occur in patients with underlying malnutrition
Respiratory failure
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Fig. 4. Mortality rates in normonatremic (hatched bars) and hyponatre-
mic (open bars) patients with a variety of illnesses.
[58, 59]. Thus the consistently higher mortality in hyponatremic
than in normonatremic patients likely reflects the nature and
severity of the underlying disease process (Table I, Fig. 4) [2,3,
16, 55—59].
One determinant of morbidity in hyponatremic patients is the
rate of decline of the plasma sodium concentration [6]. Experi-
mental studies clearly indicate that the severity of symptoms
and the degree of cerebral edema are directly related to the
speed with which hyponatremia occurs [6]. In two prospective
studies, the frequency with which severe hyponatremia was
thought to cause significant central nervous system symptoms
was 3% and 15%, respectively, of all patients with hyponatre-
mia [2, 16]. A number of clinical observations amply document
that severe morbidity and mortality accompany acute, severe
hyponatremia [4—6]. A relationship between the magnitude of
decline in plasma sodium concentration and outcome also has
been suggested. Thus mortality rates appear to be one- to
threefold higher when the serum sodium concentration is less
than 120 mEq/liter [2, 16].
In explaining the outcome of patients with hyponatremia, one
must also take cognizance of the threapy used in this disorder.
Correction of mild, asymptomatic hyponatremia (usually >120
mEq/liter) requires only water restriction and treatment of the
primary disorder [60].
If water restriction is unsuccessful, demeclocycline has be-
come the preferred therapy for chronic inappropriate secretion
of antidiuretic hormone, In 1978, Forrest et al reported that
demeclocycline was superior to lithium in the treatment of
chronic SIADH [61]. After 5 to 14 days of 600 to 1200 mg/day of
demeclocycline, mean serum sodium concentration increased
from 122 + 4 to 139 + 1 mEq/liter in 10 patients with
unrestricted water intake. In 3 patients, lithium therapy was
unsuccessful and led to central nervous system side effects in 2.
Several other therapeutic agents including urea, phenytoin, and
furosemide have been advocated as therapeutic agents in
SIADH [62—64]. None of these approaches has been demon-
strated to be superior to demeclocycline. Moreover, in compli-
ant patients, water restriction remains the cornerstone of
therapy.
The recent discovery of vasopressin antagonists by Manning
and Sawyer has opened new directions for the therapy of
hyponatremia associated with excess vasopressin [65]. Experi-
mental studies show that these vasopressin analogues inhibit
stimulation of adenylate cyclase activity by vasopressin in
isolated rat nephron segments including collecting tubules and
medullary thick ascending limbs of Henle [66]. The vasopressin
antagonists do not block the stimulatory effect of parathyroid
hormone or calcitonin on adenylate cyclase activity in the
appropriate nephron segments 166]. The vasopressin antago-
nists also inhibit vasopressin-stimulated hydraulic conductivity
in perfused rabbit cortical collecting tubules [661. Finally, these
agents have been shown to reverse the pathologic water reten-
tion that occurs in glucocorticoid and mineralocorticoid defi-
ciency [67]. Thus these agents ultimately might prove to be of
therapeutic benefit in selected hyponatremic states. To date, no
information on the use of these agents in clinical disorders that
are characterized by water retention is available.
Treatment of severe, symptomatic hyponatremia is contro-
versial. If left untreated, either death or severe neurologic
disability can result [4—6]. Unfortunately, treatment itself can
produce serious disability. Recent experimental and clinical
observations have been interpreted as suggesting that rapid
correction of hyponatremia, especially chronic hyponatremia,
can lead to central pontine myelinolysis [68—751. This syn-
drome, a demyelinating disease of the pons, is associated with a
variety of neurologic symptoms. It occurs in patients with
alcoholism, malnutrition, and other debilitating diseases [71,
72]. The possible relationship between central pontine myelino-
lysis and correction of hyponatremia was reviewed by Ayus et
a! [3]. In the absence of overcorrection to frank hypernatremia I
do not believe that a convincing case has been made for this
association. Several observations argue against the existence of
a clearcut relationship between rapid correction of hyponatre-
mia and central pontine myelinolysis: (1) Most of the reported
patients with central pontine myelinolysis were not hyponatre-
mic [3, 72, 73]; many, in fact, were hypernatremic [72]; (2) Less
than 5% of patients with central pontine myelinolysis had a
history of rapid correction of hyponatremia [3, 71, 76];(3) In the
few instances in which central pontine myelinolysis was attrib-
uted to rapid correction of hyponatremia, rapid correction of
hyponatremia was not documented in some, and in the others
the patients were made frankly hypernatremic [3, 70]; (4) In
experimental studies of hyponatremic rats in which rapid cor-
rection of hyponatremia was associated with central pontine
myelinolysis, it is likely that overcorrection to frank hyperna-
tremia also occurred [69]; more recent experimental studies in
the rat demonstrate that rapid correction of hyponatremia with
hypertonic saline to mildly hyponatremic levels does not cause
significant brain lesions [76]; (5) Retrospective analysis reveals
that rapid correction of severely symptomatic, acute hyponatre-
mia is associated with a lower mortality rate than is slow
correction [3, 77]; and (6) Recent clinical reports, albeit involv-
ing small numbers of patients, suggest that rapid correction of
severe hyponatremia to slightly hyponatremic levels does not
produce central pontine myelinolysis [78, 79]. Thus, in severe
hyponatremic emergencies, it is unlikely that rapid correction,
that is, correction sufficient to cause serum sodium to rise by
approximately 1.5 mEq/liter/hour to mildly hyponatremic lev-
els, approximately 125 mEq/liter, leads to central pontine
myelinolysis.
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Specifically, in normovolemic patients either thought to be
symptomatic from hyponatremia or with marked hyponatremia
(<110 mEq/liter), I advocate the use of furosemide (1 mg/kg
body weight) and replacement of urinary losses with 3% NaCl
to elevate the serum sodium concentration to about 125 mEq/
liter [79].
In summary, the nature and severity of the underlying disease
state and of the magnitude and speed of decline of plasma
sodium concentration appear to be the major determinants of
the outcome in hyponatremic patients. In the occasional patient
with severe, symptomatic hyponatremia, rapid correction to a
plasma sodium concentration of about 125 mEq/liter appears to
be safe.
Questions and answers
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago): Some hormones, such as parathyroid hormone, are
secreted at a basal level whether or not there is any stimulus for
secretion [80]. Is vasopressin secreted in the this manner? If so,
could unregulated basal secretion explain some of what we
think of as SIADH?
DR. ANDERSON: As I noted previously, there are two main
stimuli for vasopressin release. Increasing osmolality is one.
Gary Robertson has shown that, as osmolality increases, vaso-
pressin release begins to occur at a certain 'threshold" osmo-
lality value [81]. This threshold value is determined by multiple
factors including age, sex, genetic variables, and perhaps
central hemodynamic status. Typically, the relationship be-
tween increased osmolality and increased vasopressin release is
linear and very steep, small increases in osmolality producing
appreciable increases in vaspressin. The relationship between
the strength of nonosmotic stimuli and vasopressin release is
quite different. For example, as much as a 10% to 15% decrease
in extracellular fluid volume may be required to initiate vaso-
pressin release [81]. Moreover, the increase in plasma vaso-
pressin with nonosmotic stimuli is logarithmic rather than
linear. Thus whether there is "basal" secretion of vasopressin
greatly depends on the state of water balance and basal plasma
osmolality.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital, Chicago): If there is a "tonic" secretion of vasopressin,
the hormone circulates at a level that is too low to affect urinary
concentration; thus, in a sense there is a certain osmotic "set
point" at which secretion is "turned off" appropriately. Some
investigators claim that vasopressin can be measured at levels
too low to affect urinary osmolality (that is, the urine remains
maximally dilute). Others find it unmeasurable at those levels.
DR. JORDAN J. COHEN: You have emphasized appropriately
the dominant role that ADH plays in the pathogenesis of
clinically occurring hyponatremia. But it is also well established
that appreciable urinary concentration can occur in the total
absence of ADH; I believe Berliner and Davidson were the first
to demonstrate that reduced GFR or, by implication, increased
proximal sodium reabsorption, could result in water retention
by the kidney. Many of the clinical circumstances in which
hyponatremia occurs are characterized by avid proximal sodi-
um reabsorption, often in association with some reduction in
GFR. What is your current view about the relative role of these
physiologic abnormalities in the pathogenesis of hyponatremia?
DR. ANDERSON: It is my bias that ADH plays the major role
even through reduced distal delivery may contribute. Studies in
animal models of heart failure and liver disease show that
removal of the source of ADH by hypophysectomy corrects the
diluting defect by 95% [82, 83]. I think a clear-cut answer to
your question will likely be provided by studies with the newly
available, specific vasopressin antagonists.
DR. BUSHINSKY: In chronic hypernatremia, it appears that
idiogenic osmoles form in the brain and that this process
protects neurons against volume changes [84]. Is there any
evidence that chronic hyponatremia causes neurons to decrease
their effective osmolality?
DR. ANDERSON: Current concepts of cell volume regulation
suggest that many cells respond to osmotic challenge by first
exhibiting osmometric behavior followed by a regulatory vol-
ume adjustment [85]. The regulatory volume adjustment phase
involves enhanced cell solute exit and decreased cell solute
entry sufficient to return cell volume to normal [85]. Some
experimental evidence suggests that volume readjustment in the
brain occurs in chronic hyponatremia [6].
DR. COHEN: We know that in some circumstances serum
sodium can fall by 30% or more. If there were not a substantial
fall in the effective osmolality within the cell, one would have to
envision a proportionate increase in the volume of the brain;
obviously a change of that magnitude is impossible. Unless one
believes there is a barrier to water movement into brain
tissue, there must be some alteration in the osmotic activity of
the intracellular enviroment. Do you agree?
DR. ANDERSON: Your point has been brought up with regard
to SIADH. The initial observations by Schwartz and Bartter
suggested that hyponatremia could not be explained by the
positive water balance or the loss of salt, and they postulated
that there was inactivation of intracellular solutes. Either
inactivation of intracellular solutes or negative cell solute
balance (that is, cellular solute effiux greater than influx) would
be necessary to autoregulate cell volume toward normal. In
studies that we have performed in an experimental model of
SIADH, however, hyponatremia can be accounted for totally
by positive water and negative solute balances [54].
DR. JAMES BOURDEAU (Renal Division, Michael Reese Hos-
pital): Work done by Grantham et al in isolated rabbit kidney
tubules [86] and by Kregenow and coworkers in duck erythro-
cytes [87] investigating the volume response to hypotonic
challenge showed that potassium chloride appears to leave
these cells. The mechanism causing potassium chloride to exit
from mammalian cells might vary depending on the system, but
loss of these solutes appears to be one of the protective
mechanisms for minimizing cellular swelling in response to a
sudden hypoosmotic stress.
DR. ARNOLD BERNS (Staff Nephrologist, Michael Reese
Hospital): As you pointed out, the vast majority of hyponatre-
mic patients have an elevated AVP level. How do you catego-
rize the ones who don't? Occasionally we see a hyponatremic
patient with maximally dilute urine. Such patients usually have
a high urine flow and they improve rapidly, usually within the
first 24 hours. I'm not sure how to explain this, but I have
always wondered whether the rate of water intake might
transiently exceed maximal free-water clearance. If so, it might
be possible to get a transient but significant dilutional hypona-
tremia in the absence of renal disease and without secretion of
antidiuretic hormone. Do you think this actually happens?
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DR. ANDERSON: Yes. First, what is going on in hyponatremic
patients who don't have measurable ADH? The ADH assay is
difficult, and only 1.0 pg/mI increases urinary osmolality by 250
mOsm/kg H20. The traditional explanation has been that AVP
is difficult to measure in the very low range. There might be
other explanations for persistent hypoosmolality with very low
ADH levels as well. There may be an entity of reset osmostat in
which, for example, one regulates around a plasma osmolality
of 275 mOsm/kg H20. There is some evidence that this might
happen in pregnancy. Second, the diluting capacity can be
overwhelmed if one drinks a great deal of water in a hurry. This
happens predominantly in psychotic patients. We have seen
instances in which patients took a hose attached to the tap and
put it down their stomach. Although you or I can get rid of 20 or
25 liters of water in a day, we can't get rid of large quantities in
one or two hours. There is no doubt that, acutely, our renal
diluting capacity can be overwhelmed.
DR. SERAFINO GARELLA (Department of Medicine, Michael
Reese Hospital): I believe that those patients who develop
hyponatremia because of excessive water intake of a magnitude
sufficient to outstrip their normal diluting capacity can be
distinguished on clinical grounds because they have a large
output of maximally dilute urine. This finding should markedly
simplify the differential diagnosis.
DR. COHEN: Another setting in which transient, non-ADH-
mediated water retention might occur is in individuals who are
ingesting very low solute loads, especially when the minimum
urinary osmolality that can be achieved is a little higher than
normal. For example, the elderly patient who is subsisting on a
tea-and-toast diet and who has a slight intrinsic impairment in
diluting capacity might be unable to excrete ordinary amounts
of ingested water fast enough to avoid hyponatremia. Would
you agree with that?
DR. ANDERSON: Yes.
DR. LINDHEIMER: Concerning the ability of an individual to
maintain a chronic hyponatremic state in the absence of vaso-
pressin: I'm aware of one circumstance in animals in which this
occurs. Some years ago we studied gestation in Brattleboro rats
with hereditary diabetes insipidus, a strain in which the homo-
zygous animals produce no vasopressin. We observed that the
osmotic threshold for drinking was descreased during gestation
in these animals and that the gravid homozygous animal was
able to maintain its plasma osmolality at approximately 10
mOsm/kg below nongravid levels throughout the gestation.
Thus the assertion that individuals with normal renal function
cannot drink enough to maintain a chronically hypoosmotic
state might not be valid.
DR. GARELLA: What are your thoughts regarding two condi-
tions in which, to my knowledge, hyponatremia has not been
reported to be associated with increased AVP levels, namely,
the so-called "cerebral salt wasting" syndrome, and the hypon-
atremia that is occasionally seen following the use of thiazide
diuretics, and which has been attributed to potassium
depletion?
DR. ANDERSON: I have to confess that I haven't studied the
issue of cerebral salt wasting very much so I can't answer your
question. But I would like to dispute the notion that patients
with SIADH are "salt wasters." Schwartz and Bartter de-
scribed their patients as having renal salt-wasting. I don't think
that is a totally accurate characterization. In the steady state,
patients with SIADH put out as much salt in the urine as they
take in. Moreover, from a physiologic perspective, SIADH is a
modestly volume-expanded state, In the setting of SIADH and
positive water balance, some of the retained water remains in
the extracellular fluid. Thus, the GFR is high, and cardiac
output can be on the high side. In that setting with a high filtered
load of sodium, decreased proximal reabsorption, and variable
aldosterone secretion (both low and high values have been
reported), I think that salt in the urine reflects sodium intake. A
number of years ago Nolph and Schrier demonstrated that a
patient with well-documented SIADH who had a very low
sodium intake could reduce urine sodium excretion to negligible
levels [88]. Thus although we traditionally talk about SIADH,
particularly SIADH associated with intracranial pathology, like
cerebral salt wasting, I think that patients with these disorders
excrete urinary sodium equivalent to their sodium intake.
The second question brought up by Dr. Garella is a more
problematic area, that is, the pathogenesis of hyponatremia that
occurs in the potassium-depleted patient. These patients are
almost invariably taking thiazide diuretics [89]. In patients
taking thiazides, it traditionally has been thought that natriure-
sis leads to modest volume depletion the volume depletion in
turn stimulates ADH secretion, and following ingestion of a lot
of water, hyponatremia results, A recent study of thiazide-
induced hyponatremia demonstrated that urinary concentration
of sodium and potassium exceed 150 mEq/liter, whereas the
serum values of these electrolytes were less than 110 mEq/liter
[90]. Thus thiazides can potentially induce hyponatremia with-
out producing changes in waterbalance. The observation has
been made repetitively that many patients with thiazide-in-
duced hyponatremia have marked hypokalemia and, in selected
circumstances, restore their plasma sodium to normal with
potassium repletion alone [91]. Fichman et al postulated that
hypokalemia or potassium depletion somehow lowers the os-
motic or nonosmotic threshold for release of vasopressin. No
data are available to support this contention as far as I can tell.
Another possible explanation is that as one becomes potassium
depleted, potassium shifts from intracellular to extracellular
sites. Concomitantly, sodium and hydrogen ions go inside the
cell and are relatively inactive as intracellular solutes. This is an
area that is poorly understood.
DR. COHEN: Dr. Anderson, in your opinion does chronic,
asymptomatic hyponatremia result in any adverse
consequences?
DR. ANDERSON: If you are talking about a sodium concentra-
tion in the 125 to 130 mEq/liter range that has developed slowly,
I don't think there is much morbidity or mortality from the
hyponatremia by itself.
DR. GARY TOBACK (Renal Section, Mitchell Hospital): You
indicated that the plasma AVP concentration is often strikingly
elevated during the intra- and postoperative periods, and can
remain so for at least a day or two after surgery. Three
questions spring to mind. First, why don't these patients
routinely manifest the pressor effects of AVP when such high
concentrations are present in the plasma? Second, surgeons
commonly administer large amounts of hypotonic fluids in the
postoperative period, so why is the frequency of hyponatremia
only 4.5% or so? Third, what counterregulatory mechanisms
blunt these expected pressor and antidiuretic effects of the
hormone when it is present at such a high concentration for a
prolonged period?
DR. ANDERSON: With regard to the frequency of the develop-
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ment of hyponatremia, we studied only patients whose serum
sodium level was less than 130 mEq/liter. In our hospital, a
normal value is about 141 I mEq/liter. If we included all
sodium values less than 138 mEq/liter, we would have a much
higher incidence of postoperative hyponatremia. With regard to
hypertension, AVP levels of 20 to 30 pg/mI might be required to
consistently exert a vasoconstrictor effect, and those levels are
not seen in these patients. The factors that counteract the
vasoconstrictor effects of vasopressin are not well established,
but might include prostacyclin and the kinins.
DR. LINDHEIMER: Do you think that AVP is the only humoral
agent responsible for urinary concentration? I ask this question
because those of us who use radioimmunoassays to measure
this hormone occasionally encounter individuals who concen-
trate their urine, but whose AVP levels are below the limits of
detection of our assay. Such observations suggest that the AVP
molecule in some individuals might be altered and not recog-
nized by the antiserum. One might also speculate that in some
physiologic or pathophysiologic states there are circulating
substances capable of stimulating adenyl cyclase production in
critical areas of the nephron. What is your opinion of that?
DR. ANDERSON: I agree that some day we might identify
another antidiuretic hormone, or at least systems that modify
antidiuretic hormone. For example, in the isolated perfused
cortical collecting tubule, atrial natriuretic factor is an inhibitor
of vasopressin. I think there are a lot of substances such as
adenosine, prostaglandins, atrial natriuretic factor, and the
kinins that influence cellular regulation of vasopressin action. I
wouldn't rule out an as-of-yet unidentified substance that also
contributes to urine concentrating ability.
DR. FREDRIC C0E (Renal Section, Mitchell Hospital): The
message I take home is that water elimination is diminished in
hospitalized patients because vasopressin is often elevated,
albeit by a number of factors. Thus, virtually all serious
hyponatremia in hospitalized patients is iatrogenic. So if we
simply improve the way in which we administer water, the
whole problem should disappear. It seems to me from what
you've said that better education is the best treatment for
hospital-acquired hyponatremia.
DR. ANDERSON: That is precisely the message I intended to
deliver. Hyponatremia is often iatrogenic and is preventable.
Recall that in two large prospective studies hyponatremia was
hospital-acquired in 67% of cases [2, 16].
DR. KAI LAU (Renal Division, Michael Reese Hospital): You
have shared with us some recent observations from which you
concluded that chronic exposure to vasopressin can desensitize
the collecting tubule cell to its action. How would you extrapo-
late this observation to the patient with SIADH in whom ADH
levels are persistently high?
DR. ANDERSON: We recently have generated data in cultured
collecting tubular cells that demonstrate that chronic exposure
to vasopressin densensitizes these cells [91]. Thus if you expose
the collecting tubular cells in culture to vasopressin for one
hour, wash them, and rechallenge them with vasopressin, you
will see a marked decrease in adenylate cyclase activity [91].
This densensitization can be prevented by pertussis toxin, so
we believe that the inhibitory guanine nucleotide regulatory
protein might play a role in this desensitization.
DR. COHEN: Could you clarify an issue that has always
puzzled me about chronic hyponatremia in patients with
SIADH? It is well established that ADH administered chroni-
cally to an animal with a fixed water intake causes maximal
water retention only over the first few days. Thereafter, urine
becomes less concentrated and hyponatremia is at least partial-
ly repaired. In other words, the animal "escapes" from the
action of ADH in much the same way that animals escape from
the effects of DOCA. I would be interested, first of all, in your
ideas about the mechanism of the ADH-escape phenomenon
and, second, in why we don't observe such escape in the
clinical setting.
DR. ANDERSON: If you expose an animal to high concentra-
tions of vasopressin and a fixed intake of free water, renal water
retention occurs and hyponatremia develops. However, a new
steady state is ultimately reached during which plasma sodium
remains constant and renal excretion of all ingested water
occurs [54]. Thus, after a period of water retention, escape from
the hydroosmotic effect of vasopressin can be documented. It is
clear that this phenomenon can only occur in the presence of
positive water balance [54, 921. The precise mechanisms of
escape from vasopressin are not clear. However, I think that
prostaglandin E2 contributes to the escape [54]. In addition,
plasma volume expansion as well as an increase in cardiac
index, plasma volume, renal blood flow, and glomerular filtra-
tion rate all accompany the escape phenomenon and can
contribute to its generation [54].
Reprint requests to Dr. R. Anderson, University of Colorado Health
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